Plattform Life Sciences 2/2017 - Steckbriefe

5 Unternehmen im Portrait

Unternehmen Steckbriefe 5 Unternehmen im Portrait In der diesjährigen Ausgabe „Personalisierte Medizin“ präsentieren sich fünf Unternehmen auf der Suche nach starken, verlässlichen Partnern, Kunden und Kooperationen. Die Steckbriefe liefern Details, um Ideen für potenzielle Geschäfte zu generieren und eine Kontaktaufnahme zu ermöglichen. Beim Lesen der Steckbriefe werden Sie feststellen, wie vielfältig die Tätigkeits gebiete der Unternehmen sind. Für den Inhalt ist allein der Werbekunde verantwortlich, Es erfolgt keine redak- tionelle Prüfung. apceth Biopharma Indivumed Lipotype Medigene Mologen S. 38 S. 39 S. 39 S. 40 S. 40 apceth Biopharma GmbH Field of Activity Pharmaceutical development of innovative cell therapies based on genetic engineering of MSC; CDMO for Advanced Therapy Medicinal Products (ATMPs). Ownership structure and Financing apceth is a privately held company owned by the investors Santo Holding GmbH and FCP Biotech Holding GmbH, and the company founders. Partners apceth has established collaborations with numerous industrial, clinical and academic partners. Technology Proprietary therapeutic platform based on genetic engineering of MSC for the generation of targeted cell therapy strategies for various medical indications. Products/Services Genetically engineered MSC therapies for 1. immunomodulation & regeneration (GvHD, COPD, Diabetes T1), and 2. immuno-oncology (solid cancer); CDMO for ATMPs. Unique Selling Point Innovative biopharmaceuticals based on genetically engineered MSC and the proprietary platform for their design; complete GMP manufacturing in-house (apceth GMP facilities). Address Location Ottobrunn Haidgraben 5 D-85521 Ottobrunn Location Munich Max-Lebsche-Platz 30 D-81377 Munich Telephone/Telefax +49 89 7009608-0 / -130 E-mail contact@apceth.com Web Address www.apceth.com Date of Incorporation/ Number of Employees 2007 / approx. 80 Dr. Christine Günther, CEO apceth Biopharma – The cell engineering company! PROPRIETARY TECHNOLOGY & PRODUCTS • Leader in the development of cell- based gene therapies • Genetically engineered mesenchymal stem cell (MSC) therapeutics • Immunomodulation & immuno-oncology: - Product group 1: chronic infl am- mation & autoimmunity - Product group 2: solid cancer • The fi rst clinical trial worldwide with genetically engineered MSC CONTRACT DEVELOPMENT & MANU- FACTURING ORGANISATION (CDMO) • Reliable, experienced and high perfor- mance partner • Complex cell-based and gene therapy products (ATMPs) • Process, product and assay development • GMP manufacturing and logistics • GMP-certifi ed since 2010 38 ls 02-2017 „Personalisierte Medizin“

Seitenübersicht